Kirk RutterSpecial Advisor, Patient Experience
Kirk is a technologist for a London University. He became a volunteer patient on the 2015 Imperial College clinical study of psilocybin therapy for treatment-resistant depression (TRD).
Driven by the scheduled status of psilocybin that limits its use in research, Kirk talks openly about his experience with depression and the profound beneficial long-lasting effects of psilocybin therapy following the trial.
As one of the few people who have received this treatment, I fully appreciate the potential of psilocybin therapy for use with treatment-resistant depression. Shortly after the trial I remember thinking it was shocking that this treatment might never be widely available. I first met COMPASS to record a short film to talk about my experience. I was struck by their professionalism, ethics and commitment to patients.